Is adagrasib currently covered by medical insurance?
Adagrasib is a targeted therapy drug targeting the KRAS G12C mutation. It has been used in the treatment of some patients around the world. However, as of now, adagrasib has not been officially launched in my country, and therefore has not been included in the national medical insurance directory. If domestic patients need medicines, they can only purchase them through overseas medical channels. Access is relatively limited, and the overall cost is high, which puts a certain amount of financial pressure on patients.
In overseas markets, the original drug of adagrasibu is already on the market, mainly the American version. In terms of price, due to high R&D and marketing costs, a box of the American version of adagrasib costs up to hundreds of thousands of yuan. Such high costs have caused many patients to face a greater financial burden during the actual treatment process and have to seek more economically feasible alternative sources of drugs.
In order to meet the treatment needs of more patients, some foreign regions have launched generic drugs of adagrasib. Taking the generic version produced in Laos as an example, each box costs about more than 3,000 yuan, which has a clear price advantage compared to the original drug. The ingredients of generic drugs are basically the same as those of original drugs. After standardized production processes, they can provide more treatment opportunities for patients with limited economic conditions and effectively alleviate the problem of high drug costs.
Although generic drugs are more affordable, patients still need to be cautious when choosing and ensure that the sources of drugs are regular and reliable. At the same time, before officially using adagrasib or its generic drugs, it is recommended that patients consult a professional doctor and develop a personalized treatment plan according to their own condition to ensure the efficacy and safety of the drug and maximize the treatment effect.
References:https://www.krazati.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)